Stock Evaluator: Evogene Ltd. (EVGN)

Evogene Ltd. EVGN

$0.39 0.02 5.58%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 147,838
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Commentary & Analysis


Financial Summary

Share Statistics EVGN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $5.6 $211.8 5%
Shares Out (Mil) 12.2 55.4 24%
Institutional Ownership 39.3% 93.0% 16%
Float (Mil) 14.5 41.5 24%
Beta 0.70 0.99 40%
Avg Daily Volume (000s) 1,113 553 70%
Price Change
(52-week)
(70.3%) 42.8% 12%
Growth EVGN Industry
Median
Percentile
(All Stocks)
Sales (5yr) 31.3% 13.2% 90%
Net Income (5yr) 18.3% (10.3%) 71%
EPS (5yr) 33.5% 15.8% 84
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.7%) (15.7%) 47%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.190) ($1.100) ($0.600)
Month Ago EPS ($0.190) ($1.100) ($0.600)
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.270) ($1.700) ($0.800)
Year/Year Chg 84.5% (38.8%) (75.0%)
Financials EVGN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $2 $41 3%
Net Income (TTM) (Mil) ($9) ($44) 29%
EPS (TTM) ($0.901) ($1.500) 21%
Operating Cash Flow (TTM) (Mil) ($11) ($35) 20%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $1 $4 18%
Enterprise Value (Q1) (Mil) $8 $147 7%
Valuation EVGN Industry
Median
Percentile
(All Stocks)
P/B na 2.01 na
P/E na 17.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.0 na
Ratios EVGN Industry
Median
Percentile
(All Stocks)
Gross Margin (67.6%) 67.9% 2%
Net Margin (547.6%) (50.6%) 1%
ROA (33.4%) (47.4%) 15%
ROE na (53.1%) na
Liabilities to Assets 57.1% 29.7% 51%
F-Score 2 3 na

Evogene Ltd. did not pass any screens on 11/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors